Tashkent Pediatric Medical Institute, Tashkent, the Republic of Uzbekistan Tashkent Pediatric Medical Institute, Tashkent, the Republic of Uzbekistan

Main Article Content

S.U. Ahmedova
Z.S. Kadyrova


Background. The article describes the results of the studies of diabetic nephropathy in obese patients with type 2 diabetes mellitus (DM). The aim of the study is to investigate the combination of obesity and renal pathology in patients with type 2 diabetes mellitus. Materials and methods. The study included 50 patients with type 2 DM (17 men and 33 women), mean age 58.5 ± 7.0 years treated at the Republican Specialized Scientific and Practical Centre of Endocrinology in 2014–2016. The patients were randomized into 2 groups: with obesity (BMI > 30 kg/m2; n = 38) and without it (BMI < 30 kg/m2; n = 12). Exclusion criteria included manifested diabetic nephropathy (DN) (glomerular filtration rate (GFR) below 60 ml/min/m2, albuminuria over 2 g/24 hr), hematuria, acute cardiovascular events less than last 6 month ago, age over 70 years. Anthropometric parameters included body mass index, waist and hips circumference, waist-to-height ratio. Serum creatinine, uric acid, triglycerides levels, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glycosylated hemoglobin were determined. Severity of renal pathology was estimated by GFR and albumin excretion in urine. Results. Prevalence of hyperfiltration, microalbuminuria and proteinuria increased in patients with obesity (15, 26.6, 50 %, respectively) compared to the patients without obesity (8, 11, 11 %, respectively) when the DM duration over 5 years. Patients with BMI > 30 kg/m2 more frequently presented higher blood pressure levels (arterial hypertension stage 3 in 13 %), enhanced uric acid and reduced low-density lipoprotein cholesterol level (55.1 %) than the patients with BMI < 30 kg/m2. Conclusions. The obese patients with type 2 DM and obesity (BMI > 30 kg/m2) more frequently had renal pathology than non- obese patients. It suggests an independent role of obesity in the development of DN in addition to specific mechanisms of renal pathology in diabetic patients. This effect of obesity is mediated through the enhancement of hemodynamic and metabolic disorders.

Article Details

How to Cite
Ahmedova, S., and Z. Kadyrova. “Tashkent Pediatric Medical Institute, Tashkent, the Republic of Uzbekistan Tashkent Pediatric Medical Institute, Tashkent, the Republic of Uzbekistan”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 13, no. 2, May 2017, pp. 177-80, doi:10.22141/2224-0721.13.2.2017.100609.
Clinical Diabetology


International Obesity Task force. Obesity: the Global Epidemic. International Association for the Study of Obesity [cited 2012 August 1]. Available from: http://www.worldobesity.org/.

Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148(5):852-71. doi: 10.1016/j.cell.2012.02.017.

Bruce KD, Hanson MA. The developmental origins, mechanisms, and implications of metabolic syndrome. J Nutr. 2010 Mar;140(3):648-52. doi: 10.3945/jn.109.111179.

Collins AJ, Foley RN, Herzog C, et al. US Renal Data System 2010 Annual Data Report. Am J Kidney Dis. 2011 Jan;57(1 Suppl 1):A8, e1-526. doi: 10.1053/j.ajkd.2010.10.007.

Cao H. Adipocytokines in obesity and metabolic disease. J Endocrinol. 2014;220(2):47-59. doi: 10.1530/JOE-13-0339.

Sikaris KA. The clinical biochemistry of obesity-more than skin deep. Heart Lung Circ. 2007;16(Suppl 3):S45-50. doi: 10.1016/j.hlc.2007.05.001.

Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol. 2000;278(5):817-22. PMID:10807594.

National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012 Nov;60(5):850-86. doi: 10.1053/j.ajkd.2012.07.005.

de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: An analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med. 2011;171:412-20. doi: 10.1001/archinternmed.2011.16.

Ruzicka M, Quinn RR, McFarlane P et al. Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for the management of blood pressure in CKD. Am J Kidney Dis. 2014;63(6):869-887. doi: 10.1053/j.ajkd.2014.03.003.